SCHEDULE: Frazier Life Sciences Reports Stock Transactions

Frazier Life Sciences entities and individuals report significant sales of KalVista Pharmaceuticals common stock over a 60-day period ending May 19, 2026.

Summary

• This filing details stock transactions conducted by various Frazier Life Sciences entities and individuals concerning KalVista Pharmaceuticals, Inc. common stock over the 60 days preceding May 19, 2026.
• Multiple sales of KalVista Pharmaceuticals common stock were executed by entities including Frazier Life Sciences Public Fund, L.P. (FLSPF), Frazier Life Sciences X, L.P. (FLS X), Frazier Life Sciences XI, L.P. (FLS XI), and Frazier Life Sciences XII, L.P. (FLS XII).
• These sales occurred on May 6, 2026, and May 19, 2026, with prices ranging from $26.76 to $26.825 per share.
• As of May 7, 2026, the total outstanding shares of KalVista Pharmaceuticals' common stock were reported as 53,240,888.
• Frazier Life Sciences Public Fund, L.P. reported beneficial ownership of 1,249,165 shares, representing 2.3% of the class.
• Frazier Life Sciences X, L.P. reported beneficial ownership of 427,983 shares, representing 0.8% of the class.
• Frazier Life Sciences XI, L.P. reported beneficial ownership of 145,592 shares, representing 0.3% of the class.
• Frazier Life Sciences XII, L.P. reported beneficial ownership of 6,563 shares, representing 0.0% of the class.
• James N. Topper and Patrick J. Heron, as members of FHMLS X, L.L.C., share voting and investment power over the FLS X shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant volume of stock sales reported by a major shareholder, which could be interpreted as a bearish signal.

Negatives

• Significant sales of KalVista Pharmaceuticals common stock by Frazier Life Sciences entities occurred within the reported 60-day period.
• The total number of shares sold by FLSPF, FLS X, FLS XI, and FLS XII amounts to over 3.1 million shares across the two transaction dates.

Risks

• The substantial sales by a major shareholder like Frazier Life Sciences could indicate a lack of confidence in future stock performance or a strategic shift in investment focus.
• The aggregate sales could potentially exert downward pressure on the stock price if not absorbed by market demand.

Future Outlook

The filing primarily reports past transactions and does not contain forward-looking statements or guidance from KalVista Pharmaceuticals, Inc. It details the beneficial ownership and recent trading activity of Frazier Life Sciences entities.

Industry Context

StockSavvy.ai notes that significant stock sales by venture capital firms like Frazier Life Sciences can be interpreted in various ways, including portfolio rebalancing, profit-taking, or a signal regarding the company's future prospects. Such filings are closely watched by investors for insights into the sentiment of major shareholders.

Stakeholder Impact

• Shareholders may view the significant sales by Frazier Life Sciences as a negative indicator, potentially impacting share price and investor confidence.
• The market may interpret these sales as a sign of reduced confidence in KalVista Pharmaceuticals' future growth prospects by a key investor.

Key Dates

Recommendation

The filing primarily reports past stock transactions by a significant shareholder and does not provide new operational or financial information about KalVista Pharmaceuticals. While the sales are notable, a 'hold' recommendation is appropriate pending further company-specific news or performance updates.

Keywords

KalVista Pharmaceuticals, Frazier Life Sciences, Schedule 13D, Stock Sale, Beneficial Ownership, Common Stock, SEC Filing, Venture Capital